Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.30, $0.01 better than the analyst estimate of $0.29. Revenue for the quarter came in at $2.19 billion versus the consensus estimate of $2.16 billion.

"Boston Scientific delivered excellent financial results in 2016, with accelerated revenue growth, improved profitability, and strong double digit adjusted EPS growth," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "Our strategy of category leadership in key markets and diversification into high growth adjacencies is working, and enabling continued investment in innovative medical technologies. I want to thank our employees for their commitment to advancing science and improving the lives of patients around the world."

For earnings history and earnings-related data on Boston Scientific (BSX) click here.